Quince Therapeutics (NASDAQ:QNCX) Coverage Initiated at Oppenheimer

Oppenheimer began coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report report published on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $10.00 price objective on the stock.

Several other research firms have also issued reports on QNCX. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective for the company. D. Boral Capital reissued a “buy” rating and issued a $12.00 price target on shares of Quince Therapeutics in a research report on Wednesday, February 5th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $8.00.

Quince Therapeutics Stock Down 2.2 %

Shares of Quince Therapeutics stock opened at $1.34 on Monday. The stock has a 50-day moving average price of $1.48 and a 200 day moving average price of $1.44. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The company has a market cap of $58.96 million, a P/E ratio of -1.08 and a beta of 0.71. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33.

Quince Therapeutics (NASDAQ:QNCX) last issued its earnings results on Monday, March 24th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The business had revenue of $0.17 million during the quarter. As a group, analysts expect that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Quince Therapeutics

Hedge funds have recently modified their holdings of the business. Anfield Capital Management LLC bought a new position in shares of Quince Therapeutics during the 4th quarter worth about $50,000. Virtu Financial LLC acquired a new position in shares of Quince Therapeutics in the fourth quarter valued at $55,000. Two Sigma Investments LP bought a new position in shares of Quince Therapeutics during the 4th quarter worth about $57,000. Northern Trust Corp increased its stake in Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after acquiring an additional 16,501 shares during the period. Finally, Scharf Investments LLC acquired a new position in Quince Therapeutics in the fourth quarter worth about $170,000. 30.75% of the stock is owned by institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.